SMFM 咨询系列 #51:剖宫产术后静脉血栓栓塞的预防
静脉血栓栓塞是孕产妇发病和死亡的主要原因,产后尤其是剖宫产术后风险显著升高。本咨询文件讨论剖宫产术后静脉血栓栓塞预防的不同指南,并基于现有证据给出 SMFM 推荐,涵盖机械预防、药物预防、药物选择及机构方案等。
要点
- 所有剖宫产产妇应术前开始并持续使用序贯加压装置直至完全下床活动(GRADE 1C)。
- 有深静脉血栓或肺栓塞病史者,剖宫产术后建议机械联合药物预防,药物用 6 周(GRADE 2C)。
- 有遗传性易栓症但无血栓史者,剖宫产术后同样建议机械联合药物预防 6 周(GRADE 2C)。
核心结论
- SMFM 基于现有证据提出剖宫产术后静脉血栓栓塞预防的六条推荐,涵盖机械预防、药物预防、药物选择及机构安全方案。
研究设计与样本
- 本文件为 SMFM 咨询系列 #51,讨论剖宫产术后静脉血栓栓塞预防的不同指南并基于现有证据给出推荐。
主要发现
- 静脉血栓栓塞是孕产妇发病和死亡的主要原因,产后尤其是剖宫产术后风险显著升高。
- 静脉血栓栓塞预防方法在妊娠期包括剖宫产术后存在相当大的差异。
关键数值与推荐
- 推荐所有剖宫产产妇术前开始使用序贯加压装置并持续至完全下床活动(GRADE 1C)。
- 建议有深静脉血栓或肺栓塞个人史者剖宫产术后接受机械预防(术前开始至下床活动)联合药物预防(术后 6 周)(GRADE 2C)。
- 建议有遗传性易栓症(高风险或低风险)但无血栓史者剖宫产术后接受机械预防(术前开始至下床活动)联合药物预防(术后 6 周)(GRADE 2C)。
- 推荐低分子量肝素作为妊娠期和产后首选的血栓预防药物(GRADE 1C)。
- 妊娠期 III 级肥胖女性需要药物血栓预防时,建议使用依诺肝素中间剂量(GRADE 2C)。
临床怎么用
- 剖宫产产妇术前即开始序贯加压装置并持续至完全下床活动。
- 有深静脉血栓/肺栓塞史或遗传性易栓症者,剖宫产术后联合机械与药物预防,药物用 6 周。
- 妊娠期和产后药物预防首选低分子量肝素;III 级肥胖者需药物预防时用依诺肝素中间剂量。
- 机构应建立剖宫产术后静脉血栓栓塞预防的安全集束化方案和机构方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venous thromboembolism is a major cause of maternal morbidity and mortality. The risk of venous thromboembolism is particularly elevated during the postpartum period and especially after cesarean delivery. There is considerable variation in the approach to prophylaxis of venous thromboembolism in pregnancy, including after cesarean delivery. This Consult discusses the different guidelines on prophylaxis of venous thromboembolism after cesarean delivery and provides recommendations based on the available evidence. The recommendations by the Society for Maternal-Fetal Medicine are as follows: (1) we recommend that all women who undergo cesarean delivery receive sequential compression devices starting before surgery and that the compression devices be used continuously until the patient is fully ambulatory (GRADE 1C); (2) we suggest that women with a previous personal history of deep venous thrombosis or pulmonary embolism who undergo cesarean delivery receive both mechanical (starting preoperatively and continuing until ambulatory) and pharmacologic (for 6 weeks postoperatively) prophylaxis (GRADE 2C); (3) we suggest that women with a personal history of an inherited thrombophilia (high-risk or low-risk) but no previous thrombosis who undergo cesarean delivery receive both mechanical (starting preoperatively and continuing until ambulatory) and pharmacologic (for 6 weeks postoperatively) prophylaxis (GRADE 2C); (4) we recommend the use of low-molecular-weight heparin as the preferred thromboprophylactic agent in pregnancy and the postpartum period (GRADE 1C); (5) when pharmacologic thromboprophylaxis is needed in pregnant women with class III obesity, we suggest the use of intermediate doses of enoxaparin (GRADE 2C); and (6) we recommend that each institution develop a patient safety bundle with an institutional protocol for venous thromboembolism prophylaxis among women who undergo cesarean delivery (Best Practice).
引用
- Pacheco LD, Saade G, Metz TD, et al. Society for Maternal-Fetal Medicine Consult Series #51: Thromboembolism prophylaxis for cesarean delivery. Am J Obstet Gynecol. 2020. PMID: 32360109. doi:10.1016/j.ajog.2020.04.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。